Novavax Stock Cash And Equivalents
| NVV1 Stock | EUR 8.31 0.26 3.03% |
Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.
Novavax |
Novavax Company Cash And Equivalents Analysis
Novavax's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Novavax Cash And Equivalents | 1.57 B |
Most of Novavax's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Novavax has 1.57 B in Cash And Equivalents. This is 91.26% higher than that of the Healthcare sector and 251.14% higher than that of the Biotechnology industry. The cash and equivalents for all Germany stocks is 41.9% higher than that of the company.
Novavax Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.Novavax is currently under evaluation in cash and equivalents category among its peers.
Novavax Fundamentals
| Return On Equity | -8.98 | |||
| Return On Asset | -0.32 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.66) % | |||
| Current Valuation | 484 M | |||
| Shares Outstanding | 85 M | |||
| Shares Owned By Insiders | 0.45 % | |||
| Shares Owned By Institutions | 62.33 % | |||
| Price To Book | 72.32 X | |||
| Price To Sales | 0.45 X | |||
| Revenue | 1.15 B | |||
| Gross Profit | (1.39 B) | |||
| EBITDA | (1.68 B) | |||
| Net Income | (1.74 B) | |||
| Cash And Equivalents | 1.57 B | |||
| Cash Per Share | 20.11 X | |||
| Total Debt | 323.46 M | |||
| Debt To Equity | 8.24 % | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | (7.21) X | |||
| Cash Flow From Operations | 322.95 M | |||
| Earnings Per Share | (15.18) X | |||
| Target Price | 264.2 | |||
| Number Of Employees | 1.54 K | |||
| Beta | 1.72 | |||
| Market Capitalization | 727.55 M | |||
| Total Asset | 2.58 B | |||
| Z Score | 1.2 | |||
| Net Asset | 2.58 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.